Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high-performance liquid chromatographic method with fluorescence detection

被引:29
作者
Klippert, P [1 ]
Jeanniot, JP [1 ]
Polvé, S [1 ]
Lefèvre, C [1 ]
Merdjan, H [1 ]
机构
[1] Technol Servier, F-45000 Orleans, France
来源
JOURNAL OF CHROMATOGRAPHY B | 1998年 / 719卷 / 1-2期
关键词
ivabradine;
D O I
10.1016/S0378-4347(98)00406-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive and selective high-performance liquid chromatographic method with native detection of fluorescence was developed and validated for the quantitation of ivabradine and its N-demethylated metabolite in plasma (rat, dog, human) and human urine. The procedure involves the use of an analogue as internal standard, solid-phase extraction on cyano cartridges, separation on a Nova-Pak C-8 column and fluorescence detection. Calibration curves are linear in the concentration ranges from 0.5 to 100 ng/ml in plasma and 2.0 to 500 ng/ml in urine with a limit of quantitation set at 0.5 and 2.0 ng/ml in plasma and urine, respectively. The analysis of plasma and urine samples (spiked with the analytes at low, medium and high concentrations of the calibration range) demonstrates that both analytes can be measured with precision and accuracy within acceptable limits. Quality controls spiked with analyte concentrations up to 10 000 ng/ml can also be analysed with excellent precision and accuracy after dilution of the samples. The parent drug and its metabolite are stable in plasma and urine after short-term storage (24 h at room temperature and after three freeze-thaw cycles) as well as after long-term storage at -20 degrees C (at least 6 months in animal plasma and 12 months in human plasma and urine). The method has been used to quantify both compounds in plasma and urine samples from clinical and non-clinical studies with ivabradine. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:125 / 133
页数:9
相关论文
共 7 条
[1]   Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells [J].
Bois, P ;
Bescond, J ;
Renaudon, B ;
Lenfant, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (04) :1051-1057
[2]   ACUTE AND CHRONIC CARDIAC AND REGIONAL HEMODYNAMIC-EFFECTS OF THE NOVEL BRADYCARDIAC AGENT, S16257, IN CONSCIOUS RATS [J].
GARDINER, SM ;
KEMP, PA ;
MARCH, JE ;
BENNETT, T .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 (04) :579-586
[3]   DETERMINATION OF VERAPAMIL AND NORVERAPAMIL IN HUMAN PLASMA BY LIQUID-CHROMATOGRAPHY - COMPARISON BETWEEN A LIQUID-LIQUID-EXTRACTION PROCEDURE AND AN AUTOMATED LIQUID SOLID EXTRACTION METHOD FOR SAMPLE PREPARATION [J].
HUBERT, P ;
CHIAP, P ;
CECCATO, A ;
BECHET, I ;
SIBENALERDECHAMPS, R ;
MAES, P ;
CROMMEN, J .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1992, 10 (10-12) :937-942
[4]  
RESPLANDY G, 1996, P 6 EUR C BIOPH PHAR
[5]   ANALYTICAL METHODS VALIDATION - BIOAVAILABILITY, BIOEQUIVALENCE, AND PHARMACOKINETIC STUDIES [J].
SHAH, VP ;
MIDHA, KK ;
DIGHE, S ;
MCGILVERAY, IJ ;
SKELLY, JP ;
YACOBI, A ;
LAYLOFF, T ;
VISWANATHAN, CT ;
COOK, CE ;
MCDOWALL, RD ;
PITTMAN, KA ;
SPECTOR, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (03) :309-312
[6]  
SIMON L, 1995, J PHARMACOL EXP THER, V275, P659
[7]   ELECTROPHYSIOLOGICAL EFFECTS OF S-16257, A NOVEL SINOATRIAL NODE MODULATOR, ON RABBIT AND GUINEA-PIG CARDIAC PREPARATIONS - COMPARISON WITH UL-FS-49 [J].
THOLLON, C ;
CAMBARRAT, C ;
VIAN, J ;
PROST, JF ;
PEGLION, JL ;
VILAINE, JP .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 (01) :37-42